Triple attack: radiation, immunotherapy, and chemo take on tough breast cancer
NCT ID NCT06627712
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage triple-negative breast cancer (TNBC). TNBC is harder to treat than other breast cancers, and this combination aims to boost the immune system's ability to kill cancer cells. About 318 participants will receive the treatment before surgery, and researchers will measure how many have no cancer remaining at that point.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC - TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital, Sichuan University
RECRUITINGSichuan, Chengdu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Gene-Edited immune cells tame Hard-to-Treat cancers?
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New imaging tracer could spot hidden cancers